Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

NCT03075553 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03075553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03075553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Terminated
Start date
May 17, 2017
Completion date
May 29, 2019
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blastic plasmacytoid dendritic cell neoplasm, hepatosplenic t-cell lymphoma, htlv-1 infection, nk-cell lymphoma, unclassifiable, primary systemic anaplastic large cell lymphoma, alk-negative, recurrent adult t-cell leukemia/lymphoma, recurrent anaplastic large cell lymphoma, recurrent angioimmunoblastic t-cell lymphoma, recurrent enteropathy-associated t-cell lymphoma, recurrent mycosis fungoides, refractory adult t-cell leukemia/lymphoma, refractory anaplastic large cell lymphoma, refractory angioimmunoblastic t-cell lymphoma, refractory enteropathy-associated t-cell lymphoma, refractory mycosis fungoides, refractory nasal type extranodal nk/t-cell lymphoma, refractory peripheral t-cell lymphoma, not otherwise specified